• Netarsudil (AR-13324): Unlocking Predictive siRNA Codelivery

  2026-07-16

  Explore Netarsudil’s dual mechanistic promise in Rho kinase inhibition and high-efficiency siRNA codelivery, supported by cutting-edge quantitative prediction frameworks. This article delivers strategic guidance for translational researchers seeking to bridge actin cytoskeleton modulation with next-generation combination therapies for ocular and fibrotic disease models.

• Exercise Capacity Loss Precedes Muscle Dysfunction in PH Rat

  2026-07-16

  This study reveals that reduced exercise capacity in pulmonary hypertension (PH) rat models occurs before any detectable intrinsic skeletal muscle dysfunction. The findings highlight central cardiopulmonary impairment, not skeletal muscle changes, as the primary driver of early exercise intolerance, guiding future research and therapeutic strategies.

• Berberrubine Modulates Lipid Metabolism and Gut Microbiota i

  2026-07-15

  The reference study demonstrates that berberrubine, a primary metabolite of berberine, alleviates non-alcoholic fatty liver disease (NAFLD) by regulating glucose and lipid metabolism and restoring gut microbiota balance. These findings highlight the molecular targets and mechanisms through which natural compounds may provide therapeutic benefit in metabolic liver disorders.

• Optimizing NHS-Biotin Workflow for Advanced Protein Labeling

  2026-07-15

  NHS-Biotin (N-hydroxysuccinimido biotin) enables efficient, site-specific biotinylation of proteins and antibodies, facilitating sensitive detection and purification. This article translates the latest protein engineering advances into actionable protocols, benchmarked troubleshooting, and workflow innovations for biochemical and cell biology research.

• Deuterated Tetrazole CYP51 Inhibitor Advances for IFIs Contr

  2026-07-14

  This study reports the development of a deuterated tetrazole CYP51 inhibitor (V23) with broad-spectrum antifungal efficacy, improved selectivity, and in vivo activity against drug-resistant pathogens. The findings highlight a promising strategy for overcoming resistance and safety limitations of current azole agents in invasive fungal infection management.

• Dual Luciferase Reporter Gene System: Precision in Gene Regu

  2026-07-14

  Unlock unparalleled sensitivity in transcriptional regulation studies with the Dual Luciferase Reporter Gene System. This APExBIO solution streamlines high-throughput workflows and empowers researchers to achieve reproducible, data-rich insights for gene expression regulation and promoter analysis.

• Plerixafor (AMD3100): Enhancing Assays for CXCR4 Axis Resear

  2026-07-13

  Plerixafor (AMD3100) from APExBIO empowers precision targeting of the CXCL12/CXCR4 axis, enabling robust cancer metastasis inhibition and stem cell mobilization workflows. This guide delivers stepwise protocols, troubleshooting insights, and actionable lessons drawn from pioneering in vivo studies and cross-referenced literature for high-impact experimental results.

• RUBCN Identified as Prognostic Biomarker in Breast Cancer Pr

  2026-07-13

  Yang et al. (2026) identified RUBCN as a novel prognostic biomarker and potential therapeutic target in breast cancer, using integrated bioinformatics and cellular assays. Their findings highlight RUBCN’s role in regulating cell proliferation, invasion, and autophagic flux, providing a foundation for future targeted therapy research.

• Bifendate (DDB) for Hepatoprotection: Applied Workflows & In

  2026-07-12

  Bifendate (DDB) stands out as a multi-target hepatoprotection agent with robust experimental flexibility—from inhibiting autophagy to modulating lipid metabolism and drug transporters. This guide translates recent multiomics breakthroughs and validated protocols into stepwise workflows, troubleshooting strategies, and actionable tips for maximizing DDB’s impact in liver research.

• L-NMMA Acetate in Regenerative Research: Beyond Inflammation

  2026-07-10

  Explore how L-NMMA acetate enables advanced control of nitric oxide pathways in regenerative and periodontal tissue research. This article provides a deep scientific perspective on N(G)-monomethyl-L-arginine acetate, revealing practical insights that extend beyond standard inflammation models.

• CCN1–Integrin αvβ6–TGF-β Axis in Hypertensive Brain Injury

  2026-07-09

  This study elucidates how hypertension-induced cognitive impairment is mediated by a novel CCN1–integrin αvβ6–TGF-β signaling axis that disrupts mitochondrial integrity in neurons. The findings demonstrate that diminazene aceturate, by destabilizing CCN1 mRNA, preserves mitochondrial function and reverses cognitive deficits in hypertensive models, providing a mechanistic foundation for targeted neuroprotective strategies.

• Coumestrol: Applied Workflows for Phytoestrogen Receptor Ant

  2026-07-09

  Coumestrol is a nanomolar-potency phytoestrogen estrogen receptor antagonist with unique activity at multiple nuclear receptors. This article translates its latest application in rheumatoid arthritis cell models into actionable experimental workflows, troubleshooting strategies, and cross-domain advantages for endocrine and inflammation research.

• ALDH2 Activation Delays Heart Failure by Promoting Cardiomyo

  2026-07-08

  This study demonstrates that activating ALDH2 significantly extends the proliferative window of mouse cardiomyocytes, delaying the onset of pressure overload-induced heart failure. These findings highlight a novel mechanism for cardiac regeneration and suggest new experimental avenues for ischemic cardioprotection research.

• miR-196a Drives Esophageal Adenocarcinoma via c-Myc/TERT/NFκ

  2026-07-08

  This study elucidates how miR-196a overexpression promotes the aggressiveness of esophageal adenocarcinoma by activating the c-Myc/TERT/NFκB signaling axis. The findings reveal new mechanistic links between miR-196a, EMT, and oncogenic signaling, offering insight into potential molecular interventions for Barrett's esophagus progression.

• Cabozantinib XL184: Phosphoproteomic Adaptation & RCC Strate

  2026-07-07

  Explore how Cabozantinib (XL184) drives timescale-dependent phosphoproteomic remodeling and motility adaptation in renal cell carcinoma (RCC). This thought-leadership piece bridges mechanistic insight with strategic guidance, incorporating new evidence on chronic kinase inhibitor exposure and actionable recommendations for translational researchers.

16338 records 1/1090 page Next 12345 下5页 Last page